Revised International Staging System (R-ISS) stage-dependent analysis uncovers oncogenes and potential immunotherapeutic targets in multiple myeloma

  1. Bo Gong  Is a corresponding author
  2. Ling Zhong
  3. Peng Hao
  4. Qian Zhang
  5. Tao Jiang
  6. Huan Li
  7. Jialing Xiao
  8. Chenglong Li
  9. Lan Luo
  10. Ping Shuai
  11. Liang Wang
  12. Yuping Liu
  13. Yi Shi
  14. Wei Zhang  Is a corresponding author
  1. University of Electronic Science and Technology of China, China
  2. Chengdu University of Traditional Chinese Medicine, China

Abstract

Multiple myeloma (MM) accounts for ~10% of all haematologic malignancies. Little is known about high intratumour heterogeneities in patients stratified by the Revised International Staging System (R-ISS). Herein, we constructed a single-cell transcriptome atlas to compare differential expression patterns among stages. We found that a novel cytotoxic plasma cell (PC) population exhibited with NKG7 positive was obviously enriched in stage II patients. Additionally, a malignant plasma cell population with significantly elevated expression of MKI67 and PCNA was associated with unfavourable prognosis and Epstein-Barr virus (EBV) infection in our collected samples. Moreover, Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) was found and verified to promote proliferation of MM cell lines, suggesting RRM2 may serve as a detrimental marker in MM. The percentages of CD8+ T cells and NKT cells decreased along with R-ISS stages, reflecting the plasticity of the tumour immune microenvironment. Importantly, their crosstalks with myeloid cells and PC identified several potential immunotargets such as SIRPA-CD47, and CD74-MIF, respectively. Collectively, this study provided an R-ISS-related single-cell MM atlas and revealed the clinical significance of novel PC clusters, as well as potential immunotargets in MM progression.

Data availability

Sequencing data have been deposited in GEO under accession code GSE176131.

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Bo Gong

    Department of Health Management, University of Electronic Science and Technology of China, ChengDu, China
    For correspondence
    gongbo2007@hotmail.com
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2763-6829
  2. Ling Zhong

    Department of Health Management, University of Electronic Science and Technology of China, ChengDu, China
    Competing interests
    The authors declare that no competing interests exist.
  3. Peng Hao

    Department of Orthopaedics, University of Electronic Science and Technology of China, ChengDu, China
    Competing interests
    The authors declare that no competing interests exist.
  4. Qian Zhang

    Department of Health Management, University of Electronic Science and Technology of China, ChengDu, China
    Competing interests
    The authors declare that no competing interests exist.
  5. Tao Jiang

    Department of Hematology, University of Electronic Science and Technology of China, ChengDu, China
    Competing interests
    The authors declare that no competing interests exist.
  6. Huan Li

    Department of Health Management, University of Electronic Science and Technology of China, ChengDu, China
    Competing interests
    The authors declare that no competing interests exist.
  7. Jialing Xiao

    Department of Health Management, University of Electronic Science and Technology of China, ChengDu, China
    Competing interests
    The authors declare that no competing interests exist.
  8. Chenglong Li

    Department of Hematology, University of Electronic Science and Technology of China, ChengDu, China
    Competing interests
    The authors declare that no competing interests exist.
  9. Lan Luo

    Chengdu University of Traditional Chinese Medicine, Chengdu, China
    Competing interests
    The authors declare that no competing interests exist.
  10. Ping Shuai

    Department of Health Management, University of Electronic Science and Technology of China, ChengDu, China
    Competing interests
    The authors declare that no competing interests exist.
  11. Liang Wang

    Department of Health Management, University of Electronic Science and Technology of China, ChengDu, China
    Competing interests
    The authors declare that no competing interests exist.
  12. Yuping Liu

    Department of Health Management, University of Electronic Science and Technology of China, ChengDu, China
    Competing interests
    The authors declare that no competing interests exist.
  13. Yi Shi

    Department of Health Management, University of Electronic Science and Technology of China, ChengDu, China
    Competing interests
    The authors declare that no competing interests exist.
  14. Wei Zhang

    Department of Orthopaedics, University of Electronic Science and Technology of China, ChengDu, China
    For correspondence
    zhangwspine@163.com
    Competing interests
    The authors declare that no competing interests exist.

Funding

National Natural Science Foundation of China (Youth Funds,82002212)

  • Ling Zhong

Science & Technology Department of Sichuan Province (Applied Basic Research,2022YFS0100)

  • Peng Hao

Chengdu Science and Technology Bureau (Applied Basic Research,2019-YF05-00572-SN)

  • Ling Zhong

China Postdoctoral Science Foundation (general program,2019M663567)

  • Ling Zhong

UESTC (Basic scientific research,ZYGX2020J024)

  • Ling Zhong

UESTC (Medicine-engineering interdisciplinary,ZYGX2021YGLH006)

  • Ling Zhong

Science &Technology Department of Sichuan Province (Outstanding Youth Fund,2022JDTD0024)

  • Bo Gong

Chengdu Science and Technology Bureau (Applied Basic Research,2022-YF05-01625-SN)

  • Bo Gong

Sichuan cadre health care project (Sichuan cadre health care project,2022-216)

  • Wei Zhang

UESTC (Medicine-engineering interdisciplinary,ZYGX2021YGLH204)

  • Wei Zhang

The roles of the funders were to do single cell sequence, analysis data, and verify the conclusions.

Ethics

Human subjects: Written informed consents were obtained from all subjects. All experimental procedures were approved by the Medical ethics committee of Sichuan Provincial People's Hospital and carried out in accordance with the principles of the Declaration of Helsinki. ALL of the patients signed the informed consent containing contact Information, the purpose of the study, risks and benefits from this study, consent to publish the manuscript. The protocol numbers was 2020-240.

Copyright

© 2022, Gong et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,152
    views
  • 157
    downloads
  • 6
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

Share this article

https://doi.org/10.7554/eLife.75340

Further reading

    1. Cancer Biology
    Han V Han, Richard Efem ... Richard Z Lin
    Research Article

    Most human pancreatic ductal adenocarcinoma (PDAC) are not infiltrated with cytotoxic T cells and are highly resistant to immunotherapy. Over 90% of PDAC have oncogenic KRAS mutations, and phosphoinositide 3-kinases (PI3Ks) are direct effectors of KRAS. Our previous study demonstrated that ablation of Pik3ca in KPC (KrasG12D; Trp53R172H; Pdx1-Cre) pancreatic cancer cells induced host T cells to infiltrate and completely eliminate the tumors in a syngeneic orthotopic implantation mouse model. Now, we show that implantation of Pik3ca−/− KPC (named αKO) cancer cells induces clonal enrichment of cytotoxic T cells infiltrating the pancreatic tumors. To identify potential molecules that can regulate the activity of these anti-tumor T cells, we conducted an in vivo genome-wide gene-deletion screen using αKO cells implanted in the mouse pancreas. The result shows that deletion of propionyl-CoA carboxylase subunit B gene (Pccb) in αKO cells (named p-αKO) leads to immune evasion, tumor progression, and death of host mice. Surprisingly, p-αKO tumors are still infiltrated with clonally enriched CD8+ T cells but they are inactive against tumor cells. However, blockade of PD-L1/PD1 interaction reactivated these clonally enriched T cells infiltrating p-αKO tumors, leading to slower tumor progression and improve survival of host mice. These results indicate that Pccb can modulate the activity of cytotoxic T cells infiltrating some pancreatic cancers and this understanding may lead to improvement in immunotherapy for this difficult-to-treat cancer.

    1. Cancer Biology
    2. Immunology and Inflammation
    Almudena Mendez-Perez, Andres M Acosta-Moreno ... Esteban Veiga
    Short Report

    In this study, we present a proof-of-concept classical vaccination experiment that validates the in silico identification of tumor neoantigens (TNAs) using a machine learning-based platform called NAP-CNB. Unlike other TNA predictors, NAP-CNB leverages RNA-seq data to consider the relative expression of neoantigens in tumors. Our experiments show the efficacy of NAP-CNB. Predicted TNAs elicited potent antitumor responses in mice following classical vaccination protocols. Notably, optimal antitumor activity was observed when targeting the antigen with higher expression in the tumor, which was not the most immunogenic. Additionally, the vaccination combining different neoantigens resulted in vastly improved responses compared to each one individually, showing the worth of multiantigen-based approaches. These findings validate NAP-CNB as an innovative TNA identification platform and make a substantial contribution to advancing the next generation of personalized immunotherapies.